Objective: The aim was to validate the SYM VEIN consensus 3D scoring tool in chronic venous disease (CVD).
Methods: This was a prospective cohort study with a total of 35 consecutive patients with CVD. Patients with CVD undergoing saphenectomy were assessed with the revised Venous Clinical Severity Score (r-VCSS), the CIVIQ-20 quality of life score questionnaire, and the SYM VEIN consensus statement 3D system, pre-operatively and four weeks post-operatively. The total 3D score was tested for reliability, construct validity, and responsiveness.
Results: The total 3D score demonstrated good reliability and internal consistency (Cronbach's alpha 0.85). Principal component analysis identified three groups of symptoms (paraesthesia, burning pain, and pruritus, vs. heaviness, sensation of swelling and aching/pain, vs. restless leg and throbbing pain) demonstrating a high intragroup correlation and likely to share similar pathophysiology, indicative of adequate construct validity. The total 3D score showed a significant correlation with r-VCSS and CIVIQ-20 score (rho .46, p = .005 and rho .65, p < .001, respectively) indicative of adequate convergent validity. After saphenectomy, significant reductions (p < .001) of the total 3D, and 3D scores for all but two individual venous symptoms were observed, indicative of excellent responsiveness. Median total 3D score was reduced from 31 to 6 (83.8% decrease, p < .001), median r-VCSS was reduced from 6 to 0 (100% decrease, p < .001), and median CIVIQ-20 score was reduced from 24 to 14 (40% decrease, p < .001). The difference of median percentage change between r-VCSS and CIVIQ-20 score vs. total 3D score was significant (p = .005 and p < .001, respectively).
Conclusion: The total SYM VEIN 3D score has good reliability, construct validity and excellent responsiveness, although less prone to change after saphenectomy compared with r-VCSS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejvs.2020.06.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rib-sparing subclavian vein decompression in venous thoracic outlet syndrome.
J Plast Reconstr Aesthet Surg
January 2025
Clinical Laboratory for Bionic Extremity Reconstruction, University Clinic for Plastic Reconstructive and Aesthetic Surgery, Medical University Vienna, Vienna, Austria; University Clinic for Plastic Reconstructive and Aesthetic Surgery, Medical University, Vienna, Austria. Electronic address:
Objective: Venous thoracic outlet syndrome (VTOS), a compression syndrome of the subclavian vein at the costoclavicular junction, is commonly treated with first rib resection. This invasive procedure carries a risk of serious complications. The purpose of this single-center cross-sectional study was to evaluate the long-term outcome of non-bony decompression by resection of the subclavius muscle and tendon and to provide a detailed description of the procedure.
View Article and Find Full Text PDFThe VIVID trial 12-month outcomes of the venous stent for the iliofemoral vein using the Duo venous stent system.
J Vasc Surg Venous Lymphat Disord
October 2024
Department of Interventional Radiology, Endovascular Consultants, Wilmington, NC.
Objective: There are varying anatomical and mechanical demands of stent placement in the iliofemoral venous segment; the Duo Venous Stent System is designed to address these issues. The purpose of the VIVID (Venous stent for the Iliofemoral Vein Investigational clinical trial using the Duo Venous Stent System) study was to investigate the safety and efficacy of the Duo Venous Stent System for the treatment of patients with nonmalignant iliofemoral venous obstructive disease.
Methods: This was an international, prospective, multicenter, single-arm study that enrolled patients with symptomatic nonthrombotic (NT), post-thrombotic (PTS), or acute deep vein thrombotic (aDVT) iliofemoral venous outflow obstruction.
Analysis of Venous Insufficiency Risk Factors and Demographic Characteristics among Nurses: An Analytical Cross-Sectional Study.
Medicina (Kaunas)
September 2024
Department of Cardiovascular Surgery, Faculty of Medicine, Başkent University, 06790 Ankara, Türkiye.
Article Synopsis
- Chronic venous insufficiency (CVI) is prevalent among nurses, affecting 65% of the sample studied, and significantly impairs their quality of life and job performance.
- The study found that factors such as chronic diseases, pregnancy, and being over the age of 26.5 significantly increase the risk of developing CVI, particularly in women.
- The researchers advocate for the implementation of risk screening and educational programs to prevent CVI among nurses, given its high and concerning prevalence in this healthcare profession.
An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1.
PLoS One
July 2024
Institute of New Drug Development Research, CdmoGen Co., Ltd., Seoul, Korea.
In previous animal model studies, we demonstrated the potential of rAAV2-sVEGFRv-1, which encodes a truncated variant of the alternatively spliced soluble version of VEGF receptor-1 (VEGFR1), as a human gene therapy for age-related macular degeneration (AMD) and diabetic retinopathy (DR). Here, we elucidate in vitro some of the mechanisms by which rAAV2-sVEGFRv-1 exerts its therapeutic effects. Human umbilical vein endothelial cells (HUVECs) were infected with rAAV2-sVEGFRv-1 or a control virus vector in the presence of members of the VEGF family to identify potential binding partners via ELISA, which showed that VEGF-A, VEGF-B, and placental growth factor (PlGF) are all ligands of its transgene product.
View Article and Find Full Text PDFProgranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results.
Nat Med
May 2024
Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, New York, NY, USA.
Article Synopsis
- GRN mutations lead to a condition known as FTD-GRN, which causes frontotemporal dementia; PR006 is a new gene therapy aimed at delivering the granulin gene using an adeno-associated virus.
- In initial studies, PR006 showed effectiveness in improving various pathological conditions related to FTD-GRN in animal models and was generally well tolerated in non-human primates.
- An ongoing human trial has reported that PR006 was safe for administration with some transient increases in progranulin levels in cerebrospinal fluid, although some patients experienced treatment-related adverse events, such as CSF pleocytosis and deep vein thrombosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!